Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran ; Hereditary Angioedema Patient-Focused Research at AAAAI 2026 03 March
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM 02 March
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates 26 February
